OTC: DHTI

Dalrada Technology Group, Inc.

CIK 0000725394 · SIC 7363 · Help Supply Services

Micro Revenue $20M Assets $18M as of Aug 16, 2026

Moving the world forward takes bold resolve that turns ideas into actions and builds real-time solutions that positively impact people and the planet. Dalrada Financial Corporation (“Dalrada” or the “Company”) accelerates positive change for current and future generations by harnessing true… About this business →

Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.

Sign up free

Want to see a complete report first? Today's free report (HPQ 10-Q) is open in full — no account needed.

10-Q Filed May 21, 2026 · Period ending Mar 31, 2026

Summary not yet generated.

8-K Filed May 1, 2026 · Period ending Apr 24, 2026

Summary not yet generated.

Partner

Trade DHTI commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

10-Q Filed Feb 23, 2026 · Period ending Dec 31, 2025

Summary not yet generated.

8-K Filed Jan 27, 2026 · Period ending Jan 21, 2026

Summary not yet generated.

8-K Filed Jan 20, 2026 · Period ending Jan 20, 2026

Summary not yet generated.

10-K Filed Sep 30, 2025 · Period ending Jun 30, 2025

Summary not yet generated.

10-K Filed Jan 13, 2025 · Period ending Jun 30, 2024

Summary not yet generated.

Latest financial statements

From 10-Q filed May 21, 2026 (period ending Mar 31, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.

As filed

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

Description Three months ended March 31, 2026 Three months ended March 31, 2025 Nine months ended March 31, 2026 Nine months ended March 31, 2025
Revenues 1,942,865 4,092,398 8,720,236 12,712,133
Revenues related party 624,239 481,878 1,205,587 1,007,656
Total revenues 2,567,104 4,574,276 9,925,823 13,719,789
Cost of revenues 1,786,660 3,169,317 7,460,304 10,316,781
Gross profit 780,444 1,404,959 2,465,519 3,403,008
Operating expenses:
Selling, general and administrative 4,064,964 5,343,732 14,642,615 18,109,736
Total operating expenses 4,064,964 5,343,732 14,642,615 18,109,736
Loss from operations (3,284,520) (3,938,773) (12,177,096) (14,706,728)
Other income (expense):
Interest expense (1,053,546) (298,028) (2,631,664) (2,397,642)
Interest income 39 17,881 5,095 58,163
Other expense (7,747) (2,034) (4,317) (784,959)
Gain (loss) on foreign exchange 19,487 (1,575) 20,225 70,084
Total other expense, net (1,041,767) (283,756) (2,610,661) (3,054,354)
Loss before taxes (4,326,287) (4,222,529) (14,787,757) (17,761,082)
Provision for Income Taxes 26,180 7,524
Net loss (4,326,287) (4,222,529) (14,813,937) (17,768,606)
Other comprehensive loss
Foreign currency translation 102,480 (52,333) 262,466 (2,679)
Comprehensive loss (4,223,807) (4,274,862) (14,551,471) (17,771,285)
Net income (loss) attributable to noncontrolling interests 960 (27,030) (9,682) (52,507)
Net loss attributable to Dalrada Technology Group Inc. stockholders (4,327,247) (4,195,499) (14,804,255) (17,716,099)
Net loss per common share to Dalrada stockholders basic (0.04) (0.05) (0.14) (0.19)
Net loss per common share to Dalrada stockholders diluted (0.04) (0.05) (0.14) (0.19)
Weighted average common shares outstanding basic 108,488,220 92,934,331 108,488,220 92,135,080
Weighted average common shares outstanding diluted 108,488,220 92,934,331 108,488,220 92,135,080

Consolidated Balance Sheets (Unaudited)

Description March 31, 2026 (Unaudited) June 30, 2025
Assets
Current assets:
Cash and cash equivalents 82,625 172,787
Restricted cash 329,307 329,307
Accounts receivable, net 2,386,017 2,747,194
Accounts receivable, net related parties 1,769,289 1,093,620
Inventories 2,720,656 2,689,845
Prepaid expenses and other current assets 662,151 708,268
Total current assets 7,950,045 7,741,021
Long-term receivables 16,544 18,261
Long-term receivables related parties 1,464,132 913,036
Property and equipment, net 900,963 1,273,315
Goodwill 1,526,042 1,531,893
Intangible assets, net 2,814,234 3,110,826
Right-of-use asset, net Operating 2,324,783 2,629,794
Right-of-use asset, net related party - Operating 721,292 1,140,749
Total assets 17,718,035 18,358,895
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable 4,429,922 4,175,896
Accrued liabilities 2,657,754 1,256,451
Accounts payable and accrued liabilities related parties 10,523,659 3,387,977
Deferred revenue 1,640,464 1,506,686
Notes payable, current portion 9,143,168 3,937,797
Lease Liability, current portion Operating 903,174 899,402
Lease Liability, current portion related - Operating 605,567 578,631
Total current liabilities 29,903,708 15,742,840
Noncurrent payables
Notes payable, net of current portion 377,827 4,926,416
Notes payable, net of current portion related parties 6,328,054 1,701,415
Contingent consideration 211,289 211,289
Lease Liability, net of current portion Operation 1,563,870 1,850,671
Lease Liability, net of current portion related party - Operating 155,389 614,681
Total liabilities 38,540,137 25,047,312
Commitments and contingencies (Note 12)
Stockholders’ equity (deficit):
Series I preferred stock, $0.01 par value, 100,000 shares authorized, 69,965 and 55,759 shares issued and outstanding as of March 31, 2026 and June 30, 2025, respectively 700 558
Series H preferred stock, $0.01 par value, 15,002 shares authorized, issued and outstanding as of March 31, 2026 and June 30, 2025, respectively 150 150
Series G preferred stock, $0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both March 31, 2026 and June 30, 2025, respectively 100 100
Series F preferred stock, $0.01 par value, 5,000 shares authorized, issued and outstanding as of both March 31, 2026 and June 30, 2025, respectively 50 50
Common stock, $0.005 par value, 500,000,000 shares authorized, 120,157,113 and 120,157,113 shares issued and outstanding at March 31, 2026 and June 30, 2025, respectively 600,785 600,785
Common stock to be issued 18,262 7,265
Preferred stock to be issued 11,861,578
Additional paid-in capital 188,527,695 176,249,788
Accumulated deficit (210,137,584) (195,323,647)
Accumulated other comprehensive loss 111,930 (150,536)
Total Dalrada Technology Group’s stockholders’ equity (deficit) (20,877,912) (6,753,909)
Noncontrolling interests 55,810 65,492
Total stockholders’ equity (deficit) (20,822,102) (6,688,417)
Total liabilities and stockholders’ equity 17,718,035 18,358,895

Condensed Consolidated Statements of Cash Flows (Unaudited)

Description Nine months ended March 31, 2026 Nine months ended March 31, 2025
Cash flows from operating activities:
Net loss (14,813,937) (17,768,606)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 655,136 732,073
Stock compensation 410,224 1,647,067
Changes in operating assets and liabilities, net of amounts acquired or assumed in connection with acquisition:
Accounts receivable (314,492) 471,132
Other receivables 17,109 482,624
Inventories (30,811) (206,806)
Prepaid expenses and other current assets 29,008 (99,406)
Noncurrent receivables (549,379) 26,578
Accounts payable and accrued liabilities related parties 6,989,461 9,440,875
Accounts payable and accrued liabilities 1,401,303 (1,449,145)
Decrease in Right of Use Asset/Liability 9,083 27,969
Contingent consideration 209,715
Deferred revenue 133,778 341,976
Net cash used in operating activities (6,063,517) (6,143,953)
Cash flows from investing activities:
Purchase of property and equipment (287,080)
Purchase of intangibles (146,449)
Acquisition of business, net of cash (46,269)
Net cash used in investing activities (479,798)
Cash flows from financing activities:
Net proceeds (repayments) from related party notes payable 4,626,639 3,903,354
Repayments of notes payable
Net proceeds (repayments) from notes payable 656,782 1,532,573
Additional Paid in Capital 12,277,907 672,554
Stock issued (11,850,439) 114,863
Net cash provided by financing activities 5,710,889 6,223,344
Net change in cash and cash equivalents (352,628) (400,407)
Effect of exchange rate changes on cash 262,466 (2,679)
Cash and cash equivalents at beginning of period 502,094 501,927
Cash and cash equivalents at end of period 411,932 98,841
Supplemental disclosure of cash flow information:
Cash paid for income taxes 18,680
Cash paid for interest 1,277,813 2,099,614
Supplemental disclosure of non-cash investing and financing activities:
Conversion of related party notes and interest into preferred stock 17,243,235
Preferred stock issued pursuant to business combination 4,596,290
Warrants issued pursuant to acquisitions 17,245 11,496
(Decrease) Increase in right-of-use asset and liability (4,848) (27,969)

Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗

About Dalrada Technology Group, Inc.

Source: Item 1 (Business) from the 10-K filed September 30, 2025. Description as filed by the company with the SEC.

Item 1. Description of Business

Company Overview

Moving the world forward takes bold resolve that
turns ideas into actions and builds real-time solutions that positively impact people and the planet. Dalrada Financial Corporation (“Dalrada”
or the “Company”) accelerates positive change for current and future generations by harnessing true potential and developing
products and services that become transformative innovations.

Dalrada has five business divisions: Genefic,
Dalrada Climate Technology, Dalrada Precision Manufacturing, Dalrada Technologies and Dalrada Corporate. Within
each of these divisions, the Company drives transformative innovation while creating solutions that are sustainable, accessible, and affordable.
Dalrada’s global solutions directly address climate change, gaps in the health care industry, and technology needs that facilitate
a new era of human behavior and interaction and ensure a bright future for the world around us.

Genefic

Genefic delivers advanced health care solutions
with dedicated products, services, and systems. From virus and disease screening capabilities to pharmaceutical goods and holistic wellness
clinics, When the world needs advanced health care, Genefic delivers with ingenuity, accessibility, and affordability. This specialized
division is committed to developing key health products, lifesaving medications and building comprehensive systems to increase capability,
strive to keep people healthy with the goals of improving their quality of life and increasing their longevity– on a global level.

Read full description ↓

Genefic Specialty Pharmacy
(“Genefic Pharmacy”)- Genefic Pharmacy (formerly Genefic Specialty Pharmacy Rx Solutions) is an Alabama-based pharmacy
with more than 30 years of experience in the retail medical and pharmaceutical industries. Genefic Pharmacy specializes in providing expert
care and managing disease states through comprehensive prescription management, education, nursing, and total health solutions. Genefic
Pharmacy maintains pharmacy licenses in all 50 States as well as Washington D.C.

Genefic Infusion Rx-
Genefic Infusion Rx is a Louisiana-based infusion pharmacy which handles all aspects of fluid and medication infusion, via intravenous
or subcutaneous application. Genefic Infusion Rx serves as an essential with healthcare systems, enhancing the infusion process through
efficient authorization and prescription management. Its state-of-the-art compounding facility is led by one of only eight pharmacists
in Louisiana with a sterile compounding board certification, ensuring top-tier precision and quality in medication preparation.

Boost Diagnostics-
Boost Diagnostics (formerly Empower Genomics and Genefic Diagnostics) is Dalrada’s wholly owned diagnostic laboratory subsidiary
which processes molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the
virus. Boost Diagnostics has built up and maintained the testing capacity to handle surges in COVID-19 testing demands. Boost Diagnostics
also offers genetic testing capabilities including Pharmacogenomics, Nutraceutical, Nutrition/Diet DNA and Exercise/Fitness DNA tests.

Dalrada Career Institute
(“DCI”) (aka International Health Group (“IHG”)) - DCI provides highly trained nursing and medical assistants
for hospitals and home health facilities since 2006. DCI’s programs include Licensed Vocational Nurse (“LVN”), Medical
Assistant Program (“MA”), Certified Nursing Assistant (“CNA") and Home Health Aide (“HHA”) training.

1

Dalrada Climate Technology

Dalrada Climate Technology (“DCT”)
is a segment which incapsulates energy services and state-of-the-art technology within the climate sustainability space. DCT employs next-generation
technology and services which enhances clean energy efforts while reducing the world’s carbon footprint. As a premier industrial
heat pump manufacturer, Dalrada delivers innovation and efficiency, building solutions that reduce energy consumption and minimize carbon
footprints, increase operational efficiencies, meet environmental, social, and governance (ESG) goals, and lower energy costs for clients.

Dalrada Technology Limited
(“DTL”) - DTL is a holding company for all United Kingdom and European based Dalrada Climate Technology entities.

Likido Ltd. (“Likido”)
- Likido is an international engineering company developing advanced solutions for the harvesting and recycling of energy. Using its novel,
heat pump systems (patent pending), Likido is working to revolutionize the renewable energy sector with the provision of innovative modular
process technologies to maximize the capture and reuse of thermal energy for integrated heating and cooling applications. With uses across
industrial, commercial and residential sectors, Likido provides cost savings and minimized carbon emissions across global supply chains.
Likido's technologies enable the effective recovery and recycling of process energy, mitigating against climate change and expected enhancement
of quality of life through the provision of low-carbon heating and cooling systems. Likido’s products currently include the
DCT One Heat Pumps (formerly Likido®ONE) and DCT Cryo Chiller. Likido also offers heat pump solutions specifically designed for residential
purposes.

During 2023, the U.S. Government
selected DCT One Series high-performance, low-carbon heat pump for real-world testing in a prestigious clean energy program. The implementation
of the DCT One Series testing is still in process. The expected positive results should not only increase market acceleration and adoption
within the federal government acceptance of groundbreaking eco-friendly technology but should also accelerate adoption within the commercial
building industry.

Dalrada Technology Spain
L.T. (“DTS”)- DTS was established as a Spanish subsidiary of DTL for the expansion of the manufacturing and sale of the
DCT One Series and DCT Cryo Chiller throughout Europe.

Dalrada Energy Services
(“DES”)- DES provides end-to-end comprehensive energy service solutions in a robust commercial capacity. DES helps organizations
meet ESG goals and standards while mitigating negative environmental impacts.

Bothof Brothers Construction
(“Bothof”)- Bothof is a licensed general contractor which provides a wide range of development, construction and design
capabilities and expertise throughout the United States. Through Bothof’s extensive experience in construction and contracting,
the DES division can provide a myriad of additional services to its private and public works customers.

Dalrada Home Corporation
(“Dalrada Home”)- Dalrada Home Corporation was established in February of 2024. Dalrada Home’s cutting-edge sustainability
solutions are designed specifically for residential purposes. Our home heat pumps help us lead the way in providing innovative climate
technology products and services to residential customers.

Grand Entrances- Grand Entrances is a California
based custom door and hardware retail store.

Dalrada Precision Manufacturing

Dalrada Precision Manufacturing creates total
manufacturing solutions that start with the design and development of high-quality machine parts and components, and end with an efficient
global supply chain. This specialized business division can meet today’s high demands and solves industry challenges. Dalrada Precision
Manufacturing is confident that it redefines the critical quality of the world’s top components and responds with in-house research,
design, engineering, and distribution through a highly reliable global supply chain and improved time-to-market capabilities.

2

Dalrada Precision Parts
(“Precision”) - Precision extends the client its engineering and operations team by helping devise unique manufacturing
solutions tailored to their products. Dalrada Precision can enter at any stage of the product lifecycle from concept and design to mass
production and logistics.

Deposition Technologies
(“DepTec”) - DepTec designs, develops, manufactures, and services chemical vapor and physical vapor deposition systems
for the microchip and semiconductor industries.

DepTec has built an impressive
catalogue of precision OEM (Original Equipment Manufacturer) parts for PVD (Physical vapor deposition) systems and the Company’s
refurbished systems which allows clients the option of purchasing the same model of system they’ve been using for decades –but
with significant upgrades and improved efficiencies. Older systems can now operate more reliably with additional control and monitoring
plus longer lifespans. DepTec also has its own PVD and CVD (Chemical Vapor Deposition) systems, EVOS-PVD and EVOS -CVD, which deposits
metals and non-metals for microchips used in almost every standard and specialized microdevices made today and in the future. These systems
can produce a superior film layer utilized in rugged high-stress environment designs.

Ignite I.T. (“Ignite”)
- Ignite is a manufacturer and seller of eco-friendly deep cleaners, parts washers and degreasers that are specially formulated to lift
hydrocarbon-based dirt and grease from virtually all surfaces with minimal effort. Ignite products are non-flammable, non-corrosive, non-toxic,
butyl-free, water-based, and leave a light citrus scent. Ignite is developed for all surfaces suitable for water and meets or exceed the
most stringent industry-testing specifications.

Dalrada Technologies

Dalrada Technologies has worked with some of the
world’s most recognizable companies, providing digital engineering for cutting-edge software systems and offering a host of robust
digital services. This business division connects the world with integrated technology and innovative solutions, delivering advanced capabilities
and error-free results. Dalrada Technologies creates digital products with expert computer information technology and software engineering
services for a variety of technical industries and clients in both B2B and B2C environments.

Prakat (“Prakat”)
- Prakat is an ISO 9001-certified company that provides end-to-end technology services across various industries, improving the value
chain. The Company specializes in test engineering, accessibility engineering, product engineering, application modernization, billing
and revenue management, CRM, and block chain. Prakat provides global customers with software and technology solutions specializing in
Test Engineering, Accessibility Engineering, Product Engineering and Application Modernization.

Dalrada Corporate

Dalrada Corporate covers the activities which
support the entire suite of Dalrada subsidiaries. Dalrada Corporate includes the areas of administration, finance, human resources, legal
advice, information technology, and marketing. It also contains executive management and shareholder-related services.

Research and Development

We spent $0 on research and development activities
during the years ended June 30, 2025, and 2024, respectively. We anticipate that we will incur additional expenses on research and development
over the next 12 months. Our planned expenditures on our operations or a business combination are summarized under the section of this
Annual Report on form 10-K entitled “Management’s Discussion and Analysis of Financial Position and Results of Operations”.

3